KV Pharmaceutical Co.(fka KVPHQ)

[air1]

kv evamist going for fda approval kv/a back to $13 very soon

[lemm]

i still believe it go to 20 $
and i still got my 1000 piece free shares
so why not believe some day 20$

GLTO

[Superfly15]

Absolute silence in here today...where are those two that said it was going to the 1s soon... LOL

[TaxiCaT]

That's what i'm wondering -

Good volume and a huge % gain today off of no news -

Hmmm...........

[lemm]

wou, what is happening ??
are we back in the running
GLTO go KVA GO

[Superfly15]

I hope it does...those spec long term 2.50 calls are looking better all the time.

[rekcusdo]

I doubt it. The stock SHOULD be trading at about 1.40.

[Gonzo10000]

I guess I'm just trigger happy. I'm wondering if this thing will go below 1.00? It sure looks that way.

[rekcusdo]

Way too early. Lol...

[Superfly15]

Looks like you covered all those shorts too early there bud

[rekcusdo]

I doubt it.

[lemm]

are we going up ,back to the moon
i still got 1000 shares for free so lets go up upup up

go KVA

[Superfly15]

Already knew you were short but thanks for letting us know that you say its ok to go up now.

[Gonzo10000]

Another down day for KV/A. I'm officially out of this stock as of today. Yes, I sold the thing short. Please feel free to pump the heck out of the stock again.

[rekcusdo]

I don't believe hedge funds have to register with the SEC...so I don't think they'd have to report either.

[Gonzo10000]

HA HA so true!

I have a question. Do Hedge Funds have to file with the SEC when they close a short position? The reason I'm asking is a couple hedge funds reported that they purchased a ton of KV stock. I can not see why they would buy into this stock now so I'm wondering if they had to report the buy because they were buying back the shares to close their shorts positions.

[rekcusdo]

Only for medicaid though. Small population of peeps. Not great news for kv, but theyve heard worse this month. Lol

[Gonzo10000]

Another good doc to review when considering KV.

https://www.cms.gov/CMCSBulletins/downloads/Makena-CMCS-Info-Bulletin-03-30-2011.pdf

[Gonzo10000]

Here is an interesting tidbit of info that pretty much underlines why KV is going down the flusher.

Please Read:

http://dch.georgia.gov/vgn/images/portal/cit_1210/48/42/169845946Makena.pdf

Basically the state of Georgia is mandating that Doctors prescribing Makena MUST justify why Makena is a better option then the compounded version when prescribing. This means that Doctors in Georgia most likely will take the path of least resistance when prescribing Progesterone and prescribe the compounded version when dealing with Medicaid. I would not be surprised if other states take this example as guidance and go in the same direction. So Sad for KV they blew it again!

[rekcusdo]

And remind me what the stock price was last fall? A dollar or so? And now they are 200 mill more in debt? Yahhhhh...me thinks 5 dollars is not even close to the bottom on this one.

[Blade$dream]

correct rekcusdoo....but I will let it ride....no metter what...have a nice weekend!

[Superfly15]

They also started producing their first product again since shutdown last fall before the Makena approval. It will take time, but each and every product they bring back & initially bring to market will contribute to the bottom line.

[rekcusdo]

Well, you indicated differently in your original post: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=61842233

There, it did seem as though you cared what the stock PPS was doing now. But since you've changed your story now, I'll respond accordingly... KV.A COULD recover over the "years to come" but it won't be from Makeva. They'll need another trick up their sleeve. And now that they have such a negative PR running around, that will take some time to recover from. I could see some insurance companies not do business with KV.A for the sole reason that they don't want to be associated with the "baby killers" of the pharmaceutical market (whether the term is justified or not).

[Blade$dream]

I do not care what tha PPS does now or next month....I'm in this one for the next years to come(I sold already a few thousand and take some nice profit)....just some free shares to Rock and rollll

[rekcusdo]

I didn't understand your first sentence because it was a run on...but for your second, I agree with you. My buddy got out at 11 bux at my advice (thank goodness) and I think he's still upset he didn't take my advice when it was at 13.50!

[rekcusdo]

...Also a valid arguement... ;)

And how cunning of your to support your claim with not data or news, but a winky emote instead. Lol.

Sorry, but the technicals support that, without FDA exclusivity on this drug, the stock is worth what it was in early February (before the whole FDA news came to light). I'm expecting this stock to settle at around 2.50 based on charts...though personally I think its worth about 90 cents based on fundamentals, considering they now have 200 million extra in debt that they didn't have before.

[Superfly15]

Keep right on talking, Makena will still sell the profits were just cut in half. I think people are just pissed off that they chose to run the mouth instead of buy in at 4$ and make a quick 25%.

[Blade$dream]

no it isn't

[rekcusdo]

Well....thats not entirely true. At least not the insinuation that there is no value in this company. Technically, the company has the same value it did BEFORE the Makeva debacle started minus 200 million dollars. So...it was trading at 1.50 before this happened. With its current O/S, I'd say it should be trading about...what...80 cents? 90 cents maybe?

[rekcusdo]

Haha...sorry buddy, but thats a pipe dream. This is just a pump. Nothing more.

[Gonzo10000]

And the pumping of this stock continues. The facts are: The company has lost it's exclusivity and new FDA approved solutions are coming to the market by end of year. KV has lost the support and confidence of key parties namely the FDA and March of Dimes. The management of the company is totally screwed up.

Where is the value in this company? BTW- The market for this trug is pretty small. This is not Viagra or some sort of fantastic new drug that can be marketed to millions of people. Again, where is the value?

[Blade$dream]

COME ON KV_A KEEP ON GOING UP FROM NOW !!!

[Gonzo10000]

More Competition for KV's Makena:

3:17 pm ET 04/06/2011 - Reuters

By Rajarshi Basu and Krishnakali Sengupta

BANGALORE, April 6 (Reuters) - Columbia Laboratories Inc and Watson Pharmaceuticals Inc said a late-stage study showed that their vaginal gel helped reduce incidence of premature birth by almost 45 percent in women with short cervical length, improving the drug's chances of getting a marketing nod.

Columbia Labs shares, which have more than doubled in value since December 6 -- when the company said the drug, Prochieve, had met the main trial goal of significantly reducing the risk of premature birth -- were trading down 2 percent at $3.89 at noon on Wednesday on Nasdaq. They had earlier touched a new 52-week high of $4.31.

"This (Wednesday's) data very much supports approval, the reason is it shows good statistical significance," Benchmark Company analyst Raymond Myers said.

The companies said they were on track to file marketing application for the drug -- a hormone-containing vaginal gel -- in the second quarter of this year.

In December last year, the drug Prochieve, met the main goal of its late-stage trial by significantly reducing premature birth risks. .]

The latest data presented the numerical evidence, compared with the December data, Myers, who has a "buy" rating and a price target of $7 on the Columbia Labs stock, said.

Preterm birth affects 10-12 percent of all pregnancies in the United States and costs about $26 billion annually. Recently, the U.S. health regulators approved a similar drug by K-V Pharmaceutical Co <KVa.N>.

The new set of data suggested that the drug significantly lowers risk of preterm birth before 33 weeks gestation, compared with those treated with a dummy drug.

The drug was also associated with a significant reduction in respiratory distress syndrome, neonatal morbidity or mortality event and birth weight.

Watson shares were up about a percent at $58.40 on the New York Stock Exchange. (Reporting by Krishnakali Sengupta and Rajarshi Basu in Bangalore) ([e-mail]; Within U.S. [phone]; Outside U.S. [phone]; Reuters Messaging: [e-mail]))

[Gonzo10000]

Down again today pending more news. It's really looking like the market has begun to give up on KV. The company really needs to say and do something positive to stop their slide.

[Gonzo10000]

Another down day. The market has not been kind to the new pricing idea. I'm thinking that KV is going to have to come down on the price again to appease the powers that be. No free lunch for KV/A.

I'm sure another shoe will be falling any time now.

[Gonzo10000]

This morning is not looking good for KV/A.

[hrocks66]

Adage Capital thinks this is a buy

http://www.streetinsider.com/Hedge+Funds/Adage+Capital+Discloses+6%25+Stake+in+KV+Pharma+(KV-A)/6408585.html

[Gonzo10000]

It appears there's something to chase. Stock price took another hit today. not looking good in the hood.

[Superfly15]

lololol, have you ever heard of ambulance chasers ???

[Gonzo10000]

OMG! Possible Securities Laws Violation Connected to Makena.

K-V Pharmaceutical Company again under Investor Investigation over possible Securities Laws Violatio PDF Print E-mail

The Shareholders Foundation announces that an investigation for investors in K-V Pharmaceutical Company over possible securities laws violations was initiated and stockholders in KV Pharmaceutical should send an email to [e-mail]

An investigation on behalf of investors of K-V Pharmaceutical Company (NYSE:KV.A) over possible violations of Federal Securities Laws in connection with Makena was announced.



If you purchased shares of K-V Pharmaceutical Company (Public, NYSE:KV.A), and/or if you have any information relating the investigation, you have certain options and you should contact the Shareholders Foundation at [e-mail] or call +1(858) 779 - 1554.



The investigation by a law firm focuses on certain statements made in connection with Makena.



Makena is a drug treatment indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.



St. Louis based K-V Pharmaceutical’s 12 months Total Revenue decreased from $424.31million reported on March 31, 2007 to $152.22million reported on March 31, 2010. Its Net Income over the same time frame went from $58.56million to a Net Loss of $283.61million.



Shares of K-V Pharmaceutical Company (NYSE: KV.A) traded in 2006 as low as $1.698 per share and increased during 2007 to as high as $31.02 per share. In 2008 shares fell from as high as $28.20 in January to $2.26 per share in December. During 2009 and 2010 KV.A fell to as low as $0.65, respectively $0.64 per share.



On February 4, 2011, K-V Pharmaceutical disclosed that the U.S. Food and Drug Administration (“FDA”) granted approval for Makena.. KV Pharmaceuticals said that “Makena will be available through specialty pharmacies and distributors by prescription only and is subject to all U.S. guidelines applicable to dispensing an FDA-approved prescription product”



K-V Pharmaceuticals’ class A shares increased from $1.53 on Feb 3 to close at $3.88 per share on February 4, 2011 and continued to increase to as high as $13.07 per share on March 8, 2011.

On March 30, 2011 the FDA announces that” FDA understands that the manufacturer of Makena, KV Pharmaceuticals, has sent letters to pharmacists indicating that FDA will no longer exercise enforcement discretion with regard to compounded versions of Makena. This is not correct.”



According to a media report from the same day the news came after complaints earlier this month by two U.S. senators and an industry group about a significant price hike by K-V Pharmaceuticals for Makena.

Also on March 30, 2011, U.S. Senator Tom Harkin disclosed that K-V Pharmaceutical tried to stop pharmacists compounding the drug, advising them that it would be a violation of law to continue to compound Makena-like products.



KV.A shares fell from its closing price of $7.11 on March 29 to as low as $4 per share during March 30, 2011 and closed at closing price of $5.65 per share.



Those who purchased shares of K-V Pharmaceutical Company (NYSE:KV.A), and/or those who have any information relating the investigation, have certain options and should contact the Shareholders Foundation at [e-mail] or call +1(858) 779 - 1554.



Shareholders Foundation, Inc.
Trevor Allen
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: [phone]
Fax: [phone]
[e-mail]
www.ShareholdersFoundation.com

[rekcusdo]

If they knew what they were doing they wouldnt have lowered it to 690 this time. Now when that price fails, theyll have to lower it again and look even worse! Preterm drugs CANNOT cost more than 70 to 80 per dose if they want insurance companies to stamp their ok (which they really need to turn a larger profit).

Just look at the math:

Cost from preterm - 300mill per year
Number of pts receiving drug - 140k per year
When u divide total cost by number of pts, u get a risk factor of 2142 dollars per pt. So the FULL treatment must be under 2142 to have insurance companies cover it. At 20 doses, that is 107 per dose. Then of course, they must lower that by about 20% to actually attract those insurance companies.

Just saying "im sure they knew what they were doing" is not enough when the evidence points against it.

Companies CAN have bad management and kv has supported that accusation here (completely ignoring their shotty past.)

You can say "Think outside the box" all u want, but wishful thinking doesnt change the basic economics of their situation.

[Gonzo10000]

They aimed too high and the new price with the wacky discounts is not much better. At the end of the day it's going to be easy to order up a 400.00 batch of this drug from a pharmacy vs. trying to order the KV version and figur out all the discounts and managing all the paperwork.

The insurance companies, doctores, patients and Feds will not have the patience to deal with KV's strange pricing model when they can just place an order and the patient can pay out of pocket. Makes no sense.

[Superfly15]

I'm pretty sure K-V knew EXACTLY what they were doing by pricing Makena at 1500$...if they would have priced it at 690$ right away then the MOD and people like you would have been screaming bloody murder about price gouging and they would have had to go to 300$ instead.

It was a lose-lose no matter how they tried it on the initial announcement, so might as well aim high so then you can work it downwards.


Think outside the box

[rekcusdo]

Im not worried about anything. I have a friend invested in this stock but id never buy it no matter how low it goes, since the management of this company have already proven themselves to be inept. Here is a company that had an AMAZING opportunity and blew it out of sheer greed (and thats what it was...they had no logical reason to need 4 billion in profit in 1 year on 1 drug.

I love it when people on this board retort opinions (and even facts) with comments about trying to manipulate prices instead of actually trying to repsond. Lol

Ill add this too...if "your" company doesnt wise up soon and put a 2 digit price tag on this drug, theyll NEVER get exclusivity enforcement back and this stock will go back to 1 dollar where it was before granted exclusivity.

[Gonzo10000]

Calls Purchased on K-V Pharmaceutical Company (KV.A)
By Michael J. Zerinskas
Benzinga Staff Writer
April 01, 2011 1:11 PM
Symbols: KV.A
Tags:
Posted in: Long Ideas, Technicals, Trading Ideas, Options
Share
0diggsdigg

Email Article
Print Article

Shares of K-V Pharmaceutical Company (NYSE: KV.A) are lower on the session by 5.84%, currently trading at $5.64. The stock has been moving largely lower over the past three weeks and is currently consolidating between the 50-day and 200-day moving averages.

Options traders are buying calls on the name today. A short while ago the May 2011 $5.00 call was purchased 2,300 times, on the offer, on open interest of 708 contracts.

Overall call volume is now running at 2.12x the daily average with 92% of all calls traded being purchases on the offer.

K-V Pharmaceutical Company is an integrated specialty pharmaceutical company that develops, manufactures, acquires and markets branded and generic/non-branded prescription pharmaceutical products. It has offered a range of dosage form capabilities, including tablets, capsules, creams, liquids and ointments.

Read more: http://www.benzinga.com/trading-ideas/long-ideas/11/04/971438/calls-purchased-on-k-v-pharmaceutical-company-kv-a#ixzz1IIOu6bNC

[Superfly15]

You guys sure seem to be worried about it, are you looking for cheap shares?

[rekcusdo]

Yah, the FDA can come out of this looking rosy no matter what they do. They are not preventing a needed drug since a substitute exists, so with this KV.A better get on their knees and...cough, cough....beg.

[Gonzo10000]

Sorry My bad. The FDA would be crazy to give them their exclusivity back so soon. Why would the FDA be so generous now? KV bit their hand and made them look really bad.

[rekcusdo]

First, its 690 per dose, not 650. Second, the FDA nonexclusivity pact could be reevaluated. Lastly, you are right that 690 is still too high for insurance companies to consider covering the drug. Kv.a is just stupid.

[Gonzo10000]

650 per dose is not going to fly. Why would an insurance company pay when they know the patient can buy the drug on their own for 20.00 per dose. 20 x 20 = 400.00 for a twenty week course of treatment vs. 13,000 at the KV price for the same number of weeks. Do the math.